(Q38077471)

28 August 2017

1 reference

title

Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology (English)

1 reference

28 August 2017

1 reference

Huating Li

1

1 reference

28 August 2017

Jing Zhang

series ordinal

2

1 reference

28 August 2017

Weiping Jia

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

28 January 2013

1 reference

28 August 2017

published in

Frontiers of medicine

1 reference

28 August 2017

volume

7

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

25-30

1 reference

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Evolution of the Fgf and Fgfr gene families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

FGF-21 as a novel metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Regulation of fibroblast growth factor-23 signaling by klotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Klotho converts canonical FGF receptor into a specific receptor for FGF23

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 21 corrects obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

PPARalpha is a key regulator of hepatic FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

FGF21: a missing link in the biology of fasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Inhibition of growth hormone signaling by the fasting-induced hormone FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Thermogenic activation induces FGF21 expression and release in brown adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Cold-induced recruitment of brown adipose tissue thermogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11684-013-0244-8

Nutritional regulation of the insulin-like growth factors

21 January 2018

1 reference

12 December 2020

Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes.

1 reference

12 December 2020

Importance of sympathetic nerves for the stimulatory effect of cold exposure on glucose utilization in brown adipose tissue

1 reference

12 December 2020

Thermoregulation with age: restoration of beta(3)-adrenergic responsiveness in brown adipose tissue by cold exposure

1 reference

12 December 2020

Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21.

1 reference

12 December 2020

10.1007/S11684-013-0244-8

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1039158733

0 references

1 reference